Bank Of New York Mellon Corp Humanigen, Inc Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.12 - $0.23 $106,131 - $203,419	884,433 New	884,433 $127 Million
Q4 2022 Feb 14, 2023	BUY	$0.09 - $0.2 $79,598 - $176,886	884,433 New	884,433 $106,000
Q3 2022 Nov 14, 2022	BUY	$0.15 - $3.02 $89,952 - $1.81 Million	599,680 Added 2848.43%	620,733 $112,000
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $222,583 - $421,138	-126,468 Reduced 85.73%	21,053 $37,000
Q1 2022 May 11, 2022	BUY	$1.81 - $3.97 $6,029 - $13,224	3,331 Added 2.31%	147,521 $444,000
Q4 2021 Feb 11, 2022	BUY	$3.66 - $8.22 $15,053 - $33,808	4,113 Added 2.94%	144,190 $536,000
Q3 2021 Nov 12, 2021	BUY	$5.93 - $17.83 $30,782 - $92,555	5,191 Added 3.85%	140,077 $830,000
Q2 2021 Aug 11, 2021	BUY	$13.54 - $22.74 $1.53 Million - $2.57 Million	113,092 Added 518.91%	134,886 $2.34 Million
Q1 2021 May 13, 2021	SELL	$12.91 - $23.83 $31,500 - $58,145	-2,440 Reduced 10.07%	21,794 $416,000
Q4 2020 Feb 09, 2021	BUY	$7.97 - $21.66 $193,144 - $524,908	24,234 New	24,234 $424,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.